What are the instructions for using Nuvaring (etonogestrel/released levonorgestrel) for a female patient of reproductive age with no known contraindications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

NuvaRing Instructions for Use

Insert NuvaRing vaginally on any day from day 1 to day 5 of your menstrual cycle, leave it in place continuously for 3 weeks (21 days), then remove it for exactly 1 week (7 days) before inserting a new ring. 1, 2, 3

Insertion and Removal

  • Compress the ring between your thumb and index finger and insert it into the vagina, pushing it up as far as comfortable—the exact position is not critical for effectiveness. 2, 3
  • The ring remains in place for 21 consecutive days, during which it releases 15 μg ethinyl estradiol and 120 μg etonogestrel daily. 2, 4
  • After 3 weeks, remove the ring on the same day of the week it was inserted (e.g., if inserted on a Monday, remove on Monday 3 weeks later). 2, 3
  • Discard the used ring after removal—each ring is designed for single-cycle use only. 3, 4
  • After a 7-day ring-free interval, insert a new ring on the same day of the week as the previous insertion, even if bleeding has not stopped. 2, 3

Backup Contraception Requirements

  • If inserted within the first 5 days of menstrual bleeding, no backup contraception is needed. 1
  • If inserted after day 5 of your cycle, use backup contraception (condoms) or abstain from intercourse for 7 consecutive days. 1

Managing Ring Problems

If the Ring Slips Out (Expulsion)

  • If out for less than 3 hours: Rinse with cool-to-lukewarm water and reinsert immediately—no backup contraception needed. 2, 5
  • If out for more than 3 hours during weeks 1-2: Reinsert as soon as possible and use backup contraception for 7 days. 2
  • If out for more than 3 hours during week 3: Either insert a new ring immediately (skipping the ring-free week) or have your ring-free week now, then insert a new ring after 7 days. 2

If You Forget to Remove the Ring

  • If left in for up to 4 weeks total (1 week extra): Remove it, take the 7-day ring-free break, then insert a new ring—contraceptive protection is maintained. 2
  • If left in for more than 4 weeks: Remove it immediately, use backup contraception for 7 days, and consider emergency contraception if unprotected intercourse occurred. 2

If You Forget to Insert a New Ring After the Ring-Free Week

  • Insert the new ring as soon as you remember and use backup contraception for 7 days. 2
  • Consider emergency contraception if unprotected intercourse occurred during the extended ring-free interval. 1, 6

Effectiveness

  • NuvaRing has a typical-use failure rate of 9% and perfect-use failure rate of 0.3%, comparable to combined oral contraceptives and the contraceptive patch. 1
  • In clinical trials, the Pearl Index was 0.65 (95% CI 0.24-1.41), with three of six pregnancies occurring in women who violated the prescribed regimen. 2
  • Compliance rates are high at 90.8% of cycles, significantly better than daily pill-taking. 2

Common Side Effects and Monitoring

  • Most frequently reported side effects include: headache (6.6%), vaginal discharge/leukorrhea (5.3%), and vaginitis (5.0%). 2, 5
  • Estrogen-related side effects are less common than with oral contraceptives: nausea (2.8%) and breast tenderness (1.9%). 2
  • Device-related events such as ring expulsion, foreign body sensation, or coital problems occur in approximately 2.6% of users. 2
  • Blood pressure should be monitored during routine follow-up visits. 7

Absolute Contraindications

Do not use NuvaRing if you have: 1, 6

  • History of or current deep vein thrombosis or pulmonary embolism
  • History of stroke or heart attack
  • Uncontrolled hypertension
  • Breast cancer or other estrogen/progestin-sensitive cancers
  • Active liver disease or liver tumors
  • Unexplained vaginal bleeding
  • Known or suspected pregnancy
  • Age >35 years and current smoking
  • Migraine headaches with aura (especially if >35 years old)
  • Known hypercoagulable conditions

Special Situations

Vomiting or Severe Diarrhea

  • Unlike oral contraceptives, NuvaRing effectiveness is not compromised by vomiting or diarrhea since absorption occurs through the vaginal epithelium, not the gastrointestinal tract. 7, 4

Postpartum Use

  • Can be initiated ≥21 days postpartum in non-breastfeeding women without need for backup contraception if amenorrheic. 1
  • If breastfeeding, combined hormonal contraceptives like NuvaRing should generally be avoided in the first month postpartum, though can be used ≥1 month postpartum with caution. 1

Drug Interactions

  • Be aware of interactions with anticonvulsants, certain antibiotics (rifampin), St. John's wort, and some HIV protease inhibitors, which may decrease contraceptive effectiveness. 1
  • Use backup contraception when taking medications that may interfere with hormonal contraception. 1

Important Clinical Pearls

  • The ring does not need to be removed during intercourse, though it can be removed for up to 3 hours if desired. 5
  • Cycle control is excellent with NuvaRing, with 97-99% of cycles having regular withdrawal bleeding lasting 4.7-5.3 days. 3
  • The low, continuous hormone delivery results in lower systemic hormone levels compared to oral contraceptives, potentially reducing side effects. 8, 4
  • NuvaRing does not protect against sexually transmitted infections—use condoms for STI protection. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2002

Research

The combined contraceptive vaginal device (NuvaRing): a comprehensive review.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2005

Research

The contraceptive vaginal ring.

Seminars in reproductive medicine, 2010

Guideline

Contraceptive Efficacy and Safety of Ethinyl Estradiol and Levonorgestrel Combinations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Recommended Initial Birth Control Pill Regimen for Healthy Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.